Methyl-CpG binding protein 2 messenger RNA (MECP2 mRNA) (MECP2 mRNA)

Methyl-CpG binding protein 2 (MECP2) mRNA is the primary transcript of the MECP2 gene, which encodes a nuclear protein essential for normal brain development and the maintenance of synaptic function [4]. The resulting protein acts as a transcriptional regulator that binds to methylated CpG dinucleotides, influencing the expression of a wide array of genes involved in neuronal maturation and connectivity. Dysregulation of MECP2 levels is highly pathogenic; mutations leading to a loss of functional protein cause Rett Syndrome, a severe neurodevelopmental disorder, while gene duplication leads to MECP2 Duplication Syndrome [2]. Because the brain is exceptionally sensitive to MECP2 dosage, the mRNA and pre-mRNA have emerged as critical therapeutic targets for RNA-based interventions. Current pharmacological strategies utilize antisense oligonucleotides (ASOs) to precisely calibrate protein levels, either by triggering RNase H-mediated degradation of excess mRNA in duplication cases or by modulating splicing to bypass mutations in deficiency cases [1][3].

Other names

MECP2 pre-mRNAMethyl-CpG-binding protein 2 transcriptMECP2 RNAAUTSX3 transcriptMRX16 transcript

The primary mechanism of action for drugs targeting MECP2 mRNA involves the use of antisense oligonucleotides (ASOs) to modulate protein expression. For MECP2 Duplication Syndrome, ASOs bind to the mRNA and recruit RNase H to degrade the transcript, thereby reducing toxic protein levels [1][2]. In the context of Rett Syndrome, experimental approaches include splice-switching oligonucleotides to correct aberrant splicing or read-through agents to bypass premature stop codons [4]. Additionally, gene therapy constructs like TSHA-102 utilize regulatory elements to control the levels of the delivered MECP2 mRNA to ensure they stay within a physiological range [3].